 |
Top 242 Cancer treatment startups
Oct 02, 2025 | By Jason Kwon | 29 |
Oncology startups develop new cancer treatments and diagnostics technologies, like genome analysis, patient big data analyses, AI, immunotherapy, antibody therapy, gene therapy, stem cells, nanoparticles for drug-delivery...
1
Country: USA | Funding: $1.1B
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions.
2
Country: China | Funding: $504.7M
Ascentage Pharma is a China-based, global-oriented, clinical-stage biopharmaceutical company, dedicated to discovery and development of the “first-in-class” and the “best-in-class” targeted small-molecule cancer therapeutics.
Ascentage Pharma is a China-based, global-oriented, clinical-stage biopharmaceutical company, dedicated to discovery and development of the “first-in-class” and the “best-in-class” targeted small-molecule cancer therapeutics.
3
Country: Ireland | Funding: $245.9M
SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue.
SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue.
4
Country: UK | Funding: $192.5M
PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
5
Country: China | Funding: $180M
Adagene is an anticancer antibody discovery and engineering company which seeks to establish technology-driven discovery partnerships.
Adagene is an anticancer antibody discovery and engineering company which seeks to establish technology-driven discovery partnerships.
6
Country: USA | Funding: $3.9B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
7
Country: Germany | Funding: $2.1B
CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
8
Country: USA | Funding: $1.9B
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology.
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology.
9
Country: USA | Funding: $1.9B
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
10
Country: Germany | Funding: $1.9B
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
11
Country: USA | Funding: $1.6B
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers.
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers.
12
Country: USA | Funding: $1.6B
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
13
Country: USA | Funding: $1.3B
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
14
Country: USA | Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
15
Country: USA | Funding: $1.2B
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
16
Country: UK | Funding: $1.2B
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
17
Country: UK | Funding: $1.1B
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
18
Country: UK | Funding: $1.1B
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
19
Country: USA | Funding: $1B
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
20
Country: Israel | Funding: $1B
Novocure is an oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. TTFields are low intensity, alternating electric fields within the intermediate frequency range. TTFields disrupt cell division through physical interactions with key molecules during mitosis. This non-invasive treatment targets solid tumors.
Novocure is an oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. TTFields are low intensity, alternating electric fields within the intermediate frequency range. TTFields disrupt cell division through physical interactions with key molecules during mitosis. This non-invasive treatment targets solid tumors.
